The UK and US have announced a major bilateral deal that will ensure zero tariffs on UK pharmaceutical products entering the American market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that tariffs on these key exports will be held at nothing for a period of three years.
This development is in response to previous warnings to significantly raise duties on branded pharmaceutical imports, with figures floated reaching one hundred percent.
"This arrangement between the United Kingdom bolsters the international landscape for new treatments and brings much-needed balance to American-British drug exports," an announcement declared.
Trade Impact
Medicines are one of the Britain's largest export categories to the United States, which is by far the largest destination for large UK drugmakers.
Trade data show that in the year prior to last September, the UK exported pharmaceutical products worth billions to the US. This amount accounted for nearly one-fifth of British export trade in that period.
"This deal safeguards employment, increases investment and sets the stage for the UK to become a worldwide center for life sciences," a government official commented.
Detailed British Pledges
The deal includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to increase overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must pay back to the NHS to stay within budget will be restricted at 15%. Previously, repayments topped 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
This friction were exacerbated by assertions that American patients were charged several times more for the identical medicines than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been directed toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a percentage of its total funding over the previous ten-year period.
